Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Antibiotic Active Pharmaceutical Ingredient market: Global Opportunity Analysis and Industry Forecast 2020-2027 by API type (Penicillin Antibiotics, Cephalosporins Antibiotics, Carbapenem Antibiotics, Others) and by End User (Pharmaceutical Companies, Contract Manufacturing Organizations, Contract Development and Manufacturing Organizations): Global Opportunity Analysis and Industry Forecast, 2023-2032

A11502

Pages: NA

Charts: NA

Tables: NA

Active pharmaceutical ingredient is referred as the substance intended for the furnishing of the pharmacological activity or to have a direct effect on the diagnosis, cure, mitigation, prevention or treatment of the disease or also have a direct effect in restoring, correcting, modifying physiological functions in the patients. Antibiotics are the drugs used to treat infections caused by the germs or parasites by inhibiting one of the mechanisms in their body or destroying them. These drugs are used only in the cases of the bacterial or the parasitic infections. Some of the major subclasses of the antibiotics active pharmaceutical ingredients are penicillin, cephalosporins, carbapenems, macrolides, aminoglycosides, quinolones, sulfonamides, tetracyclines, and so on. This class covers the total of 28% of the antibiotic drugs. The second largest class of the antibiotics after the cephalosporins in the terms of the sales is the broad spectrum penicillin. This class covers total of 19% of the antibiotic drugs. The third largest class of the antibiotics is the fluoroquinolones. As per the Antibiotics Pharmaceutical conferences, this class covers 17% of the antibiotic drugs sales. Some examples of the antibiotic drugs are fluoroquinolones, linezolid, trimethoprim-sulfamethoxazole, metronidazole and much more.    

COVID-19 Scenario Analysis:

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunity for manufacturers of COVID-19 management drugs, as many developed countries had shortage of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future  

Top impacting factors: Market Scenario Analysis, Trends, Drivers, Impact Analysis

Rise in prevalence of infectious diseases like bacterial infections can fuel the growth of the market, increase in the number of patients of the infectious diseases can surge the usage of the antibiotic drugs and thus, boost the growth of the market. Rise in the healthcare expenditure is proving to be of great help in the growth of the market. Furthermore, increasing approvals for the generic drugs in the market can also fuel the growth of the market. Moreover, rise in R&D activities of the advanced molecules of the drug entities can increase the revenue of the antibiotic API manufacturers, which in turn fuels the growth of the antibiotic active pharmaceutical ingredient market.

However, high cost of the drug development and lack of awareness of the about utilization of the drugs and the side effects related to usage of the drugs are expected to hamper the growth of the market.

New product launches to flourish the market:

In March 2018, the announcement of the launch of generic version of the drug called doxycycline monohydrate immediate release capsules in the dose 50 mg, 75 mg, 100 mg was made by Mayne Pharma Group Limited.

In February 2021, the Glenmark Pharmaceuticals Limited announced the launch of the SUTIB oral capsule in the dose 12.5 mg, 25 mg, 50 mg. This is the oral multi-kinase inhibitor that works against the kidney cancer. 

Surge in the usage of the antibiotic API:

The increase in the incidence of infectious diseases and new innovations in the drug entity can help to increase the usage of the antibiotic drugs. Moreover, rise in spread of awareness regarding utilization of the drugs may also help to surge the usage of antibiotic API.

 

        Key benefits of the report:

  • This study presents the analytical depiction of the global antibiotic active pharmaceutical industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global Antibiotic Active Pharmaceutical Industry market share.
  • The current market is quantitatively analyzed to highlight the global Antibiotic Active Pharmaceutical Industry market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed global Antibiotic Active Pharmaceutical Industry market analysis based on competitive intensity and how the competition will take shape in coming years.

          Questions answered in the Antibiotic Active Pharmaceutical Industry Market research report:

  • What are the leading market players active in the antibiotic active pharmaceutical industry market?
  • What the current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What are the projections for the future that would help in taking further strategic steps?

Key Market Segments

  • By API type
    • Penicillin Antibiotics
    • Cephalosporins Antibiotics
    • Carbapenem Antibiotics
    • Others
  • By End User
    • Pharmaceutical Companies
    • Contract Manufacturing Organizations
    • Contract Development and Manufacturing Organizations
  • By Region
    • North America
    • Europe
    • Asia-Pacific
    • Latin America
    • The Middle East and Africa


Key Market Players

  • Aurobindo Pharma Limited
  • ACS Dobfar S.p.A.
  • Savior Lifetec Corporation
  • Shenzhen Haibin Pharmaceuticals Co. Ltd.
  • Daewoong Pharmaceutical Co., Ltd.
  • Fresnius Kabi AG
  • Others.
  • Sandoz International GmbH
  • Penam Laboratories Ltd.
  • CordenPharma International
  • Parabolic Drugs Ltd.
  • Centrient Pharmaceuticals
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE MARKET, BY API TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Api Type

    • 4.2. Penicillin Antibiotics

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Cephalosporins Antibiotics

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Carbapenem Antibiotics

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Others

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE MARKET, BY END USER

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By End User

    • 5.2. Pharmaceutical Companies

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Contract Manufacturing Organizations

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Contract Development And Manufacturing Organizations

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Api Type

      • 6.2.3. Market Size and Forecast, By End User

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Antibiotic Active Pharmaceutical Ingredient: Opportunity Analysis And Industry Forecast 2020-2027 By Api Type Market

        • 6.2.5.1. Market Size and Forecast, By Api Type
        • 6.2.5.2. Market Size and Forecast, By End User
      • 6.2.6. Canada Antibiotic Active Pharmaceutical Ingredient: Opportunity Analysis And Industry Forecast 2020-2027 By Api Type Market

        • 6.2.6.1. Market Size and Forecast, By Api Type
        • 6.2.6.2. Market Size and Forecast, By End User
      • 6.2.7. Mexico Antibiotic Active Pharmaceutical Ingredient: Opportunity Analysis And Industry Forecast 2020-2027 By Api Type Market

        • 6.2.7.1. Market Size and Forecast, By Api Type
        • 6.2.7.2. Market Size and Forecast, By End User
    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Api Type

      • 6.3.3. Market Size and Forecast, By End User

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Antibiotic Active Pharmaceutical Ingredient: Opportunity Analysis And Industry Forecast 2020-2027 By Api Type Market

        • 6.3.5.1. Market Size and Forecast, By Api Type
        • 6.3.5.2. Market Size and Forecast, By End User
      • 6.3.6. Germany Antibiotic Active Pharmaceutical Ingredient: Opportunity Analysis And Industry Forecast 2020-2027 By Api Type Market

        • 6.3.6.1. Market Size and Forecast, By Api Type
        • 6.3.6.2. Market Size and Forecast, By End User
      • 6.3.7. Italy Antibiotic Active Pharmaceutical Ingredient: Opportunity Analysis And Industry Forecast 2020-2027 By Api Type Market

        • 6.3.7.1. Market Size and Forecast, By Api Type
        • 6.3.7.2. Market Size and Forecast, By End User
      • 6.3.8. Spain Antibiotic Active Pharmaceutical Ingredient: Opportunity Analysis And Industry Forecast 2020-2027 By Api Type Market

        • 6.3.8.1. Market Size and Forecast, By Api Type
        • 6.3.8.2. Market Size and Forecast, By End User
      • 6.3.9. UK Antibiotic Active Pharmaceutical Ingredient: Opportunity Analysis And Industry Forecast 2020-2027 By Api Type Market

        • 6.3.9.1. Market Size and Forecast, By Api Type
        • 6.3.9.2. Market Size and Forecast, By End User
      • 6.3.10. Russia Antibiotic Active Pharmaceutical Ingredient: Opportunity Analysis And Industry Forecast 2020-2027 By Api Type Market

        • 6.3.10.1. Market Size and Forecast, By Api Type
        • 6.3.10.2. Market Size and Forecast, By End User
      • 6.3.11. Rest Of Europe Antibiotic Active Pharmaceutical Ingredient: Opportunity Analysis And Industry Forecast 2020-2027 By Api Type Market

        • 6.3.11.1. Market Size and Forecast, By Api Type
        • 6.3.11.2. Market Size and Forecast, By End User
    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Api Type

      • 6.4.3. Market Size and Forecast, By End User

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Antibiotic Active Pharmaceutical Ingredient: Opportunity Analysis And Industry Forecast 2020-2027 By Api Type Market

        • 6.4.5.1. Market Size and Forecast, By Api Type
        • 6.4.5.2. Market Size and Forecast, By End User
      • 6.4.6. Japan Antibiotic Active Pharmaceutical Ingredient: Opportunity Analysis And Industry Forecast 2020-2027 By Api Type Market

        • 6.4.6.1. Market Size and Forecast, By Api Type
        • 6.4.6.2. Market Size and Forecast, By End User
      • 6.4.7. India Antibiotic Active Pharmaceutical Ingredient: Opportunity Analysis And Industry Forecast 2020-2027 By Api Type Market

        • 6.4.7.1. Market Size and Forecast, By Api Type
        • 6.4.7.2. Market Size and Forecast, By End User
      • 6.4.8. South Korea Antibiotic Active Pharmaceutical Ingredient: Opportunity Analysis And Industry Forecast 2020-2027 By Api Type Market

        • 6.4.8.1. Market Size and Forecast, By Api Type
        • 6.4.8.2. Market Size and Forecast, By End User
      • 6.4.9. Australia Antibiotic Active Pharmaceutical Ingredient: Opportunity Analysis And Industry Forecast 2020-2027 By Api Type Market

        • 6.4.9.1. Market Size and Forecast, By Api Type
        • 6.4.9.2. Market Size and Forecast, By End User
      • 6.4.10. Thailand Antibiotic Active Pharmaceutical Ingredient: Opportunity Analysis And Industry Forecast 2020-2027 By Api Type Market

        • 6.4.10.1. Market Size and Forecast, By Api Type
        • 6.4.10.2. Market Size and Forecast, By End User
      • 6.4.11. Malaysia Antibiotic Active Pharmaceutical Ingredient: Opportunity Analysis And Industry Forecast 2020-2027 By Api Type Market

        • 6.4.11.1. Market Size and Forecast, By Api Type
        • 6.4.11.2. Market Size and Forecast, By End User
      • 6.4.12. Indonesia Antibiotic Active Pharmaceutical Ingredient: Opportunity Analysis And Industry Forecast 2020-2027 By Api Type Market

        • 6.4.12.1. Market Size and Forecast, By Api Type
        • 6.4.12.2. Market Size and Forecast, By End User
      • 6.4.13. Rest of Asia Pacific Antibiotic Active Pharmaceutical Ingredient: Opportunity Analysis And Industry Forecast 2020-2027 By Api Type Market

        • 6.4.13.1. Market Size and Forecast, By Api Type
        • 6.4.13.2. Market Size and Forecast, By End User
    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Api Type

      • 6.5.3. Market Size and Forecast, By End User

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Antibiotic Active Pharmaceutical Ingredient: Opportunity Analysis And Industry Forecast 2020-2027 By Api Type Market

        • 6.5.5.1. Market Size and Forecast, By Api Type
        • 6.5.5.2. Market Size and Forecast, By End User
      • 6.5.6. South Africa Antibiotic Active Pharmaceutical Ingredient: Opportunity Analysis And Industry Forecast 2020-2027 By Api Type Market

        • 6.5.6.1. Market Size and Forecast, By Api Type
        • 6.5.6.2. Market Size and Forecast, By End User
      • 6.5.7. Saudi Arabia Antibiotic Active Pharmaceutical Ingredient: Opportunity Analysis And Industry Forecast 2020-2027 By Api Type Market

        • 6.5.7.1. Market Size and Forecast, By Api Type
        • 6.5.7.2. Market Size and Forecast, By End User
      • 6.5.8. UAE Antibiotic Active Pharmaceutical Ingredient: Opportunity Analysis And Industry Forecast 2020-2027 By Api Type Market

        • 6.5.8.1. Market Size and Forecast, By Api Type
        • 6.5.8.2. Market Size and Forecast, By End User
      • 6.5.9. Argentina Antibiotic Active Pharmaceutical Ingredient: Opportunity Analysis And Industry Forecast 2020-2027 By Api Type Market

        • 6.5.9.1. Market Size and Forecast, By Api Type
        • 6.5.9.2. Market Size and Forecast, By End User
      • 6.5.10. Rest of LAMEA Antibiotic Active Pharmaceutical Ingredient: Opportunity Analysis And Industry Forecast 2020-2027 By Api Type Market

        • 6.5.10.1. Market Size and Forecast, By Api Type
        • 6.5.10.2. Market Size and Forecast, By End User
  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. ACS Dobfar S.p.A.

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Aurobindo Pharma Limited

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Centrient Pharmaceuticals

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. CordenPharma International

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Daewoong Pharmaceutical Co., Ltd.

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Fresnius Kabi AG

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Parabolic Drugs Ltd.

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Penam Laboratories Ltd.

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Sandoz International GmbH

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Savior Lifetec Corporation

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

    • 8.11. Shenzhen Haibin Pharmaceuticals Co. Ltd.

      • 8.11.1. Company Overview

      • 8.11.2. Key Executives

      • 8.11.3. Company Snapshot

      • 8.11.4. Operating Business Segments

      • 8.11.5. Product Portfolio

      • 8.11.6. Business Performance

      • 8.11.7. Key Strategic Moves and Developments

    • 8.12. Others.

      • 8.12.1. Company Overview

      • 8.12.2. Key Executives

      • 8.12.3. Company Snapshot

      • 8.12.4. Operating Business Segments

      • 8.12.5. Product Portfolio

      • 8.12.6. Business Performance

      • 8.12.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE MARKET, BY API TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE MARKET FOR PENICILLIN ANTIBIOTICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE MARKET FOR CEPHALOSPORINS ANTIBIOTICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE MARKET FOR CARBAPENEM ANTIBIOTICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE MARKET FOR CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. NORTH AMERICA ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. NORTH AMERICA ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY API TYPE, 2025-2033 ($MILLION)
  • TABLE 13. NORTH AMERICA ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 14. U.S. ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY API TYPE, 2025-2033 ($MILLION)
  • TABLE 15. U.S. ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 16. CANADA ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY API TYPE, 2025-2033 ($MILLION)
  • TABLE 17. CANADA ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 18. MEXICO ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY API TYPE, 2025-2033 ($MILLION)
  • TABLE 19. MEXICO ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 20. EUROPE ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 21. EUROPE ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY API TYPE, 2025-2033 ($MILLION)
  • TABLE 22. EUROPE ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 23. FRANCE ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY API TYPE, 2025-2033 ($MILLION)
  • TABLE 24. FRANCE ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 25. GERMANY ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY API TYPE, 2025-2033 ($MILLION)
  • TABLE 26. GERMANY ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 27. ITALY ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY API TYPE, 2025-2033 ($MILLION)
  • TABLE 28. ITALY ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 29. SPAIN ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY API TYPE, 2025-2033 ($MILLION)
  • TABLE 30. SPAIN ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 31. UK ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY API TYPE, 2025-2033 ($MILLION)
  • TABLE 32. UK ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 33. RUSSIA ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY API TYPE, 2025-2033 ($MILLION)
  • TABLE 34. RUSSIA ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 35. REST OF EUROPE ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY API TYPE, 2025-2033 ($MILLION)
  • TABLE 36. REST OF EUROPE ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 37. ASIA-PACIFIC ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 38. ASIA-PACIFIC ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY API TYPE, 2025-2033 ($MILLION)
  • TABLE 39. ASIA-PACIFIC ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 40. CHINA ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY API TYPE, 2025-2033 ($MILLION)
  • TABLE 41. CHINA ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 42. JAPAN ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY API TYPE, 2025-2033 ($MILLION)
  • TABLE 43. JAPAN ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 44. INDIA ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY API TYPE, 2025-2033 ($MILLION)
  • TABLE 45. INDIA ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 46. SOUTH KOREA ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY API TYPE, 2025-2033 ($MILLION)
  • TABLE 47. SOUTH KOREA ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 48. AUSTRALIA ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY API TYPE, 2025-2033 ($MILLION)
  • TABLE 49. AUSTRALIA ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 50. THAILAND ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY API TYPE, 2025-2033 ($MILLION)
  • TABLE 51. THAILAND ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 52. MALAYSIA ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY API TYPE, 2025-2033 ($MILLION)
  • TABLE 53. MALAYSIA ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 54. INDONESIA ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY API TYPE, 2025-2033 ($MILLION)
  • TABLE 55. INDONESIA ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 56. REST OF ASIA PACIFIC ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY API TYPE, 2025-2033 ($MILLION)
  • TABLE 57. REST OF ASIA PACIFIC ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 58. LAMEA ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 59. LAMEA ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY API TYPE, 2025-2033 ($MILLION)
  • TABLE 60. LAMEA ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 61. BRAZIL ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY API TYPE, 2025-2033 ($MILLION)
  • TABLE 62. BRAZIL ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 63. SOUTH AFRICA ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY API TYPE, 2025-2033 ($MILLION)
  • TABLE 64. SOUTH AFRICA ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 65. SAUDI ARABIA ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY API TYPE, 2025-2033 ($MILLION)
  • TABLE 66. SAUDI ARABIA ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 67. UAE ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY API TYPE, 2025-2033 ($MILLION)
  • TABLE 68. UAE ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 69. ARGENTINA ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY API TYPE, 2025-2033 ($MILLION)
  • TABLE 70. ARGENTINA ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 71. REST OF LAMEA ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY API TYPE, 2025-2033 ($MILLION)
  • TABLE 72. REST OF LAMEA ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 73. ACS DOBFAR S.P.A.: KEY EXECUTIVES
  • TABLE 74. ACS DOBFAR S.P.A.: COMPANY SNAPSHOT
  • TABLE 75. ACS DOBFAR S.P.A.: OPERATING SEGMENTS
  • TABLE 76. ACS DOBFAR S.P.A.: PRODUCT PORTFOLIO
  • TABLE 77. ACS DOBFAR S.P.A.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 78. AUROBINDO PHARMA LIMITED: KEY EXECUTIVES
  • TABLE 79. AUROBINDO PHARMA LIMITED: COMPANY SNAPSHOT
  • TABLE 80. AUROBINDO PHARMA LIMITED: OPERATING SEGMENTS
  • TABLE 81. AUROBINDO PHARMA LIMITED: PRODUCT PORTFOLIO
  • TABLE 82. AUROBINDO PHARMA LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 83. CENTRIENT PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 84. CENTRIENT PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 85. CENTRIENT PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 86. CENTRIENT PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 87. CENTRIENT PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 88. CORDENPHARMA INTERNATIONAL: KEY EXECUTIVES
  • TABLE 89. CORDENPHARMA INTERNATIONAL: COMPANY SNAPSHOT
  • TABLE 90. CORDENPHARMA INTERNATIONAL: OPERATING SEGMENTS
  • TABLE 91. CORDENPHARMA INTERNATIONAL: PRODUCT PORTFOLIO
  • TABLE 92. CORDENPHARMA INTERNATIONAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 93. DAEWOONG PHARMACEUTICAL CO., LTD.: KEY EXECUTIVES
  • TABLE 94. DAEWOONG PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
  • TABLE 95. DAEWOONG PHARMACEUTICAL CO., LTD.: OPERATING SEGMENTS
  • TABLE 96. DAEWOONG PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 97. DAEWOONG PHARMACEUTICAL CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 98. FRESNIUS KABI AG: KEY EXECUTIVES
  • TABLE 99. FRESNIUS KABI AG: COMPANY SNAPSHOT
  • TABLE 100. FRESNIUS KABI AG: OPERATING SEGMENTS
  • TABLE 101. FRESNIUS KABI AG: PRODUCT PORTFOLIO
  • TABLE 102. FRESNIUS KABI AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 103. PARABOLIC DRUGS LTD.: KEY EXECUTIVES
  • TABLE 104. PARABOLIC DRUGS LTD.: COMPANY SNAPSHOT
  • TABLE 105. PARABOLIC DRUGS LTD.: OPERATING SEGMENTS
  • TABLE 106. PARABOLIC DRUGS LTD.: PRODUCT PORTFOLIO
  • TABLE 107. PARABOLIC DRUGS LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 108. PENAM LABORATORIES LTD.: KEY EXECUTIVES
  • TABLE 109. PENAM LABORATORIES LTD.: COMPANY SNAPSHOT
  • TABLE 110. PENAM LABORATORIES LTD.: OPERATING SEGMENTS
  • TABLE 111. PENAM LABORATORIES LTD.: PRODUCT PORTFOLIO
  • TABLE 112. PENAM LABORATORIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 113. SANDOZ INTERNATIONAL GMBH: KEY EXECUTIVES
  • TABLE 114. SANDOZ INTERNATIONAL GMBH: COMPANY SNAPSHOT
  • TABLE 115. SANDOZ INTERNATIONAL GMBH: OPERATING SEGMENTS
  • TABLE 116. SANDOZ INTERNATIONAL GMBH: PRODUCT PORTFOLIO
  • TABLE 117. SANDOZ INTERNATIONAL GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 118. SAVIOR LIFETEC CORPORATION: KEY EXECUTIVES
  • TABLE 119. SAVIOR LIFETEC CORPORATION: COMPANY SNAPSHOT
  • TABLE 120. SAVIOR LIFETEC CORPORATION: OPERATING SEGMENTS
  • TABLE 121. SAVIOR LIFETEC CORPORATION: PRODUCT PORTFOLIO
  • TABLE 122. SAVIOR LIFETEC CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 123. SHENZHEN HAIBIN PHARMACEUTICALS CO. LTD.: KEY EXECUTIVES
  • TABLE 124. SHENZHEN HAIBIN PHARMACEUTICALS CO. LTD.: COMPANY SNAPSHOT
  • TABLE 125. SHENZHEN HAIBIN PHARMACEUTICALS CO. LTD.: OPERATING SEGMENTS
  • TABLE 126. SHENZHEN HAIBIN PHARMACEUTICALS CO. LTD.: PRODUCT PORTFOLIO
  • TABLE 127. SHENZHEN HAIBIN PHARMACEUTICALS CO. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 128. OTHERS.: KEY EXECUTIVES
  • TABLE 129. OTHERS.: COMPANY SNAPSHOT
  • TABLE 130. OTHERS.: OPERATING SEGMENTS
  • TABLE 131. OTHERS.: PRODUCT PORTFOLIO
  • TABLE 132. OTHERS.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE MARKET SEGMENTATION
  • FIGURE 2. GLOBAL ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE MARKET
  • FIGURE 3. SEGMENTATION ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE MARKET
  • FIGURE 11. ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE MARKET SEGMENTATION, BY BY API TYPE
  • FIGURE 12. ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE MARKET FOR PENICILLIN ANTIBIOTICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE MARKET FOR CEPHALOSPORINS ANTIBIOTICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE MARKET FOR CARBAPENEM ANTIBIOTICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE MARKET SEGMENTATION, BY BY END USER
  • FIGURE 17. ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE MARKET FOR CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 21. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 22. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 23. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 24. COMPETITIVE DASHBOARD
  • FIGURE 25. COMPETITIVE HEATMAP: ANTIBIOTIC ACTIVE PHARMACEUTICAL INGREDIENT: OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST 2020-2027 BY API TYPE MARKET
  • FIGURE 26. TOP PLAYER POSITIONING, 2024
  • FIGURE 27. ACS DOBFAR S.P.A.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 28. ACS DOBFAR S.P.A.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 29. ACS DOBFAR S.P.A.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 30. AUROBINDO PHARMA LIMITED: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 31. AUROBINDO PHARMA LIMITED: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 32. AUROBINDO PHARMA LIMITED: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 33. CENTRIENT PHARMACEUTICALS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 34. CENTRIENT PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 35. CENTRIENT PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 36. CORDENPHARMA INTERNATIONAL: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 37. CORDENPHARMA INTERNATIONAL: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 38. CORDENPHARMA INTERNATIONAL: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 39. DAEWOONG PHARMACEUTICAL CO., LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 40. DAEWOONG PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 41. DAEWOONG PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 42. FRESNIUS KABI AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 43. FRESNIUS KABI AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 44. FRESNIUS KABI AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 45. PARABOLIC DRUGS LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 46. PARABOLIC DRUGS LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 47. PARABOLIC DRUGS LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 48. PENAM LABORATORIES LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 49. PENAM LABORATORIES LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 50. PENAM LABORATORIES LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 51. SANDOZ INTERNATIONAL GMBH: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 52. SANDOZ INTERNATIONAL GMBH: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 53. SANDOZ INTERNATIONAL GMBH: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 54. SAVIOR LIFETEC CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 55. SAVIOR LIFETEC CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 56. SAVIOR LIFETEC CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 57. SHENZHEN HAIBIN PHARMACEUTICALS CO. LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 58. SHENZHEN HAIBIN PHARMACEUTICALS CO. LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 59. SHENZHEN HAIBIN PHARMACEUTICALS CO. LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 60. OTHERS.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 61. OTHERS.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 62. OTHERS.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Antibiotic Active Pharmaceutical Ingredient market: Global Opportunity Analysis and Industry Forecast 2020-2027 by API type

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue